IL-10-Inducing Compounds for Stable Immune Regulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for immune-mediated diseases focus on suppressing immunity and inflammation but fail to restore dominant immune regulation, leading to treatment resistance and relapse, and do not improve patient quality of life or reduce side effects.

Innovation Solution

Development of a compound that induces interleukin-10 (IL-10) production by immune cells, enabling the generation of IL-10-producing immune cells for adoptive cell therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If immunosuppressive drugs are used to suppress immunity and inhibit inflammation, then inflammation is reduced, but treatment resistance and relapse occur due to failure to restore dominant immune regulation

Engineering Contradiction:

ImproveinflammationVSAvoidtreatment stability

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

Instead of suppressing immune regulation (as conventional immunosuppressive drugs do), the invention inverts the approach by inducing production of IL-10, a dominant anti-inflammatory cytokine, thereby restoring dominant immune regulation through active induction rather than passive suppression

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The compound of formula (I) acts as an intermediary substance that induces immune cells to produce IL-10, serving as a mediator between the administered compound and the desired immune regulation effect, thereby achieving reliable and sustained treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If conventional immunosuppressive therapy is used, then inflammation is controlled, but patient quality of life does not improve and side effects persist

Engineering Contradiction:

ImproveinflammationVSAvoidpatient quality of life

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The compound enables immune cells to self-regulate by inducing them to produce IL-10 autonomously, allowing the immune system to serve itself in restoring balance rather than requiring continuous external suppression, thereby improving patient quality of life through sustained endogenous regulation

Inventive Principle:

Principle #25Self-service

3Object-affected harmful factors

If immunosuppressive drugs are used to treat immune-mediated diseases, then inflammation is reduced, but patients become resistant after some time

Engineering Contradiction:

ImproveinflammationVSAvoidtreatment duration

Core Design Contradiction:

Object-affected harmful factorsVSDuration of action of moving object

Solution Approach 1:

The invention changes the fundamental parameter of immune regulation from suppression to induction of dominant cytokine production, transforming the treatment mechanism to achieve sustained long-term efficacy without developing resistance

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250388551A1Compounds inducing production of proteins by immune cells

Publication Date: 2025.12.25 DEUT RHEUMA FORSCHUNGSZENT BERLIN

AI summary

The present invention relates to a compound of formula (I) and its use for inducing the production of interleukin-10 (IL-10) by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.